Bringing *science* to *life*

ANNUAL REPORT **2010-2011**

GenomeQuébec

Our vision

Genomics is a driving force critical to Québec's future.

Our values

Integrity

Abiding by the rules and acting accordingly

Honouring one's commitments

Being accountable and accepting responsibility

Cooperation
(partners and colleagues)

Building relationships based on respect

Creating conditions conducive to commitment

Supporting teamwork as a mean of reaching objectives

Innovation

Adopting better ways of doing things to achieve superior results

Promoting simple and useful solutions

Anticipating the impacts of planned changes

Corporate information

For more information, please contact the Public Affairs and Communications Department at 514 398-0668 or Louise Thibault by e-mail at lthibault@genomequebec.com

Head office Génome Québec
630 René-Lévesque Blvd. West, Suite 2660
Montréal, Québec H3B 1S6
514 398-0668 • Fax: 514 398-0883
gqinfo@genomequebec.com • www.genomequebec.com

Auditors KPMG LLP
600 de Maisonneuve Blvd. West, Suite 1500
Montréal, Québec H3A 0A3
www.kpmg.ca

Legal adviser
Me Jean Brunet • Stein Monast, LLP
70 Dalhousie Street, Suite 300
Québec, Québec G1K 4B2

Génome Canada
150 Metcalfe Street, Suite 2100, Ottawa, Ontario K2P 1P1
www.genomecanada.ca

Ministère du Développement économique, de l'Innovation et de l'Exportation du Québec
710, Place D'Youville, 3rd floor, Québec, Québec G1R 4Y4
www.mdeie.gouv.qc.ca

McGill University and Génome Québec Innovation Centre
740 Docteur-Penfield Ave., Montréal, Québec H3A 1A4
514 398-7211 • Fax: 514 398-1790
infoservices@genomequebec.com

Génome Québec and Centre hospitalier affilié universitaire régional de Chicoutimi Biobank
305 St-Vallier Street, Chicoutimi, Québec G7H 5H6
514 398-7211 • infoservices@genomequebec.com

Génome Québec, Université de Montréal and CHUM National Immune Monitoring Laboratory (NIML)
2901 Rachel Street East, Suite 22, Montréal, Québec H1W 4A4
514 398-7211 • infoservices@genomequebec.com

TABLE OF CONTENTS

Thanks to our partners

GenomeCanada

Développement économique, Innovation et Exportation Québec

MESSAGE FROM THE CHAIRMAN OF THE BOARD

As Génome Québec celebrates its 10th anniversary, I would like to honour the builders of our organization, whose contributions led to its outstanding development and gave Québec the opportunity to make headway in genomics research.

Gérald A. Lacoste
Chairman of the Board

Let us begin with those who founded Génome Québec at the end of the 90s. Back then, genomics research was taking place everywhere around the world, yet Québec and Canada lagged behind. This state of affairs did not go unnoticed by several astute politicians, academics, researchers, public servants and business people. They understood that Québec had everything to gain by charging full speed ahead in this emerging scientific niche. They then envisioned a unique model to support the development of genomics in our society. I would like to salute these visionaries, without whom Génome Québec could not have become a reality.

After its inception, Génome Québec still needed to accomplish its mission and adapt to the ever changing world of genomics. Over the years, a significant number of stakeholders have worked to this end: our past and present financial and scientific partners, including the MDEIE, Genome Canada, Québec universities and the scientific community on the one hand, and our employees, executives and managers, both previous and current, on the other. Thanks to their unflagging dedication, Génome Québec has become the performance-driven, flexible and dynamic organization it is today.

builders
visionaries
challenge for the next decade
collaborative
links

I would also like to highlight the increased collaborative links that have been forged between the private sector and academia over the past decade. Not only has this allowed genomics to flourish; it has also helped our organization gain a strong foothold in Québec's system of innovation. Moreover, it has broadened the influence of genomics and its researchers through educational initiatives and involvement in scientific and economic events.

Now that genomics is well underway in Québec, it must be more fully integrated into society. **Bringing *science* to *life***. Therein lies the challenge for the next decade, a challenge that I am certain Génome Québec will take up with full enthusiasm.

Gérald A. Lacoste
Chairman of the Board

In the last decade, genomics has undergone tremendous growth in Québec, asserting itself as a strategic technology, achieving major scientific breakthroughs and building a large network of partners. As a result, it now has a full arsenal of assets in genomics, including solid, recognized expertise, high-level resources and allies convinced of its scientific, social and economic importance. Génome Québec is proud to have helped build these assets and now counts on working to make them grow.

To that end, one of our priorities is to highlight the value of Québec's expertise in the field, both in terms of adding to it and enhancing its profile. In the first instance, this means helping make the advantages of genomics a reality for the benefit of each and every Quebecer. The second involves raising awareness among decision makers, investors and citizens of genomics' extraordinary potential for the socioeconomic growth of Québec. To tackle this priority, we plan on supporting translational research and personalized medicine and implementing communication and mobilization activities. We believe these are the steps needed to create and integrate genomics applications that will support the development of Québec society. And since these interventions require investments, we will also work on extending our network of public and private financial partners at the provincial, federal and international levels.

Growing our assets also involves ensuring the prosperity and sustainability of high-level resources located in Québec. The McGill University and Génome Québec Innovation Centre is one such example. It currently ranks among the highest performing technological genomics infrastructures in Québec and Canada, and we plan on propelling it to one of the top ten spots in North America. Another important resource is CARTaGENE and the Génome Québec and Centre hospitalier affilié universitaire régional de Chicoutimi Biobank. Their databanks and samples are a gold mine for researchers working on improving human health. We will be promoting their use through research programs.

Québec now has significant assets in genomics: solid, recognized expertise, high-level resources and allies convinced of its scientific, social and economic importance.

The year 2011-2012 promises to be a very busy one, and with the $26 million financial backing of the MDEIE, we will be able to follow them through. A portion of this sum will go toward co-funding projects selected under the 2010 Genome Canada Competition. Another is earmarked for initiatives that capitalize on today's assets in genomics in order to help build the Québec of tomorrow.

Jean-Marc Proulx
President and CEO

Jean-Marc Proulx
President and CEO

sustainability
commercialization
building the Québec of tomorrow
mobilization
assets

Ten years ago the human genome map was published.

Today, genomics is expected to help improve the well-being of populations and the wealth of nations, more quickly, more directly.

Catalina Lopez Correa
Vice President
Scientific Affairs

The year 2010-2011 marked the closing of the competitions launched by Génome Québec in fall 2009. With an injection of $27 million into genomics in Québec, this achievement is to be lauded. A portion of the funding, provided in equal parts by the Ministry of Economic Development, Innovation and Export Trade, private and public sources, was channelled to nineteen innovative Québec projects. Eighteen of them pertain to human health and are expected to have a direct impact on how we understand, diagnose and treat many diseases. A further $10 million was used to help Québec universities recruit, from outside our borders, world-class experts specialized in applied genomics in human health. These investments will help Québec maintain its ranking as a leader in human health genomics and ensure the solid performance of Québec researchers in future national and international competitions in the area.

competitiveness
success
shift in research
human health
spin-offs

Still on the investment front, the conclusion of a new promising bilateral agreement, set to confirm Québec's status as an international force, is certainly worthy of note. As part of this agreement, a first Québec-China project secured funding for the joint program Research on Genomics and Diseases initiated by the Fonds de la recherche en santé du Québec (FRSQ), Génome Québec and the National Natural Science Foundation of China.

As we know, genomics is the main pillar of personalized medicine. As such, Génome Québec plans on playing a central role in advancing this new way of practising medicine. That is why we took part in the Québec-led initiative on personalized medicine launched in 2010 by Montréal InVivo and the FRSQ. This venture resulted in a Québec strategy on personalized medicine, to be implemented by 2020. In coming years, we will pursue our involvement with this inspiring project, which is off to a strong start having received $20 million in provincial funding over four years.

This year, we also hosted two scientific cafés. Providing a unique venue for researchers and citizens to engage in discussions, the meetings helped to draw attention to the potential of genomics for solving human health and environmental problems. Seven Génome Québec-funded researchers and close to 100 participants attended the two events, a successful outcome that certainly encourages us to repeat the experience.

efforts that yielded results in 2010 and 2011

On another note, I would like to mention briefly a trend, which, I believe marks a shift in the way we see genomics research. Ten years ago the human genome map was published. Today, genomics is expected to help improve the well-being of populations and the wealth of nations, more quickly, more directly. These requirements to get results, asked by decision makers, funders and more implicitly from civil society, are apparent both here and around the world. It can be seen in the increasing focus of genomics research support programs on applied research. Evidence of this trend is present in the recent Genome Canada competitions as well as those of international funders. Another sign indicative of this shift is that researchers are being asked by funders to demonstrate that their projects will have quantifiable socioeconomic spin-offs as soon as their funding comes to term.

If Génome Québec is to continue to strengthen Québec's competitiveness in genomics, it must take into account this new reality. The translational component of our human health competition was a step in that direction. We will continue down this road in 2011-2012 by promoting academia-industry partnerships through pilot projects, among others. In addition, we will launch initiatives to facilitate networking opportunities between Québec and foreign researchers, the first of which will involve a new support program for international collaborations. By acting on these two fronts, we can both accompany the Québec genomics scientific community on the path to success and contribute to Québec's socioeconomic growth.

Catalina Lopez Correa
Vice President, Scientific Affairs

GÉNOME QUÉBEC COMPETITIONS

Research support • Nineteen Québec genomics projects secured funding through a series of competitions launched by Génome Québec in December 2009, the results of which were unveiled in October 2010. Thirteen of these projects were financed under the Human Health Research Support Program, with seven in the general stream and six in the translational stream. The remaining six qualified for funding under our Pilot Project Support Program. In total, $27 million – half from the MDEIE, the remainder from private and public funders – will be divided among the nineteen research initiatives. Génome Québec applauds the quality and relevance of the selected initiatives and congratulates the researchers behind them. For more details on the research projects, visit www.genomequebec.com.

Recruitment support • Another competition from Génome Québec, also initiated in December 2009, came to a close at the end of 2010. Part of our Human Health – Recruitment Program, it attracted to Québec Professor Mark Lathrop, a world-renowned researcher who was appointed as the Scientific Director of the McGill University and Génome Québec Innovation Centre. He also secured $5 million from the MDEIE in support of his research.

Professor Lathrop was previously based in Paris, where he headed the *Centre national de génotypage* (CNG) and the *Fondation Jean Dausset-Centre d'Etude du Polymorphisme Humain* (CEPH). His arrival in Québec will raise the international profile of the Innovation Centre and consolidate Canada's competitive position. In fact, Professor Lathrop has already played a pivotal role in the outstanding performance of the Innovation Centre at the 2010 Genome Canada Competition organized for Canadian technology centres; the Centre took second place and had its funding renewed for two years.

innovation
CARTaGENE
research support
recruitment
entrepreneurship

CARTaGENE

CARTaGENE • In October 2010, CARTaGENE completed phase A of its activities involving the collection of health information and biological samples from 20,000 Quebecers aged 40 to 69. Supporting the initiative were the Génome Québec and Centre hospitalier affilié universitaire régional de Chicoutimi Biobank, which was mandated to handle and store the biological samples. This represents a major success for all partners involved, including Génome Québec and Université de Montréal. CARTaGENE will accelerate human health research by providing scientists vast sums of data and samples from a major cohort. By December 2010, in fact, CARTaGENE had already received from researchers some thirty access requests.

GENOME CANADA COMPETITIONS

Large-Scale Applied Research Project Competition • On March 25, 2011, the projects selected as part of the 2010 Large-Scale Applied Research Project Competition were announced. Three Quebecers were among the principal researchers.

Professor John MacKay of Université Laval is co-leading the SMarTForest initiative, while Professors B. Franz Lang and Mohamed Hijri, both from Université de Montréal, will be spearheading the project "Improving Bioremediation of Polluted Soils Through Environmental Genomics."

SMarTForest • SMarTForest aims at creating tools to select the best spruce seedlings for reforestation, contributing to sustainable development. More specifically, Professor MacKay and his colleague Professor Jörg Bohlmann of the University of British Columbia, will use genomics to develop marker technologies that can rapidly identify the seedlings with the highest genetic potential in terms of growth, wood properties and insect resistance.

Improving Bioremediation of Polluted Soils Through Environmental Genomics • Professors Lang and Hijri are working on a protocol for the bioremediation of polluted sites using willows and high-performance microbes to clean up contaminated soils, in addition to developing a cost-effective, ecological bioremediation method.

Entrepreneurship Education in Genomics (EEG) Competition • Three Québec projects have successfully completed the first phase of the EEG Competition: their eligibility has been confirmed and they have been asked to submit a full proposal. Results will be announced on June 30. Launched in February 2010, the EEG Competition called on entrepreneurs to recommend innovative ways to help Genome Canada-funded researchers translate their discoveries into successful business ventures.

Childhood diseases: Advancing technology innovation through discovery • Dr. Jacques Michaud of the Centre hospitalier universitaire Sainte-Justine and Dr. Nada Jabado of the McGill University Health Centre are working with FORGE Canada (Finding of Rare Disease Genes in Canada) and the Canadian Pediatric Cancer Genome Consortium. Both of these initiatives were launched by a joint Genome Canada and Canadian Institutes of Health Research competition and received co-funding from Génome Québec. They will help identify the genes responsible for the most challenging cancers and rare diseases affecting children and lead the way to new approaches in the development of diagnostic tests and innovative treatment options.

	Number of persons employed in the 4th Quarter 2010-2011	Number of scientists trained in the 4th Quarter 2010-2011	Number of publications accepted or submitted	Number of conferences as speaker	Number of declaration of inventions or patents	Project starting date
COMPETITION III						
Sherif Abou Elela – FAEASI	12.1	2	9	24	3	Jan. 2006
Ken Dewar – Singe Vervet	4.5	2	2	4	0	Jan. 2006
Tomi Pastinen – GRID	46	20	84	35	2	April 2006
Guy A. Rouleau – S2D	22	2	3	12	1	April 2006
Jean-Claude Tardif – Pharmacogenocs	28	8	6	34	0	April 2006
John MacKay – Arborea II	46	20	49	95	0	April 2006
TOTAL	**158.6**	**54**	**153**	**204**	**6**	
INTERNATIONAL CONSORTIUM INITIATIVE						
Bartha Maria Knoppers/Thomas Hudson – P3G/CaG	33.5	24	35	54	0	April 2007
TOTAL	**33.5**	**24**	**35**	**54**	**0**	
PRIVAC COMPETITION						
Daniel Lamarre/Sylvain Meloche – ARNi Platform	7	0	0	3	0	Jan. 2008
Rafick-Pierre Sékaly – NIML Platform	18	3	2	4	2	May 2009
Michel G. Bergeron – GPOCT	13	2	1	16	1	Jan. 2008
Michael Phillips/Jean-Claude Tardif – Via-PGX	6.5	0	0	3	0	Oct. 2007
TOTAL	**44.5**	**5**	**3**	**26**	**3**	
TECHNOLOGY DEVELOPMENT COMPETITION						
Maryam Tabrizian – DevTab	8.7	8	17	9	1	July 2008
Rafick-Pierre Sékaly/Ryan Brinkman – DevSek	4	1	1	2	0	July 2008
TOTAL	**12.7**	**9**	**18**	**11**	**1**	
ABC COMPETITION						
Thomas Bureau – VEGI	14	8	0	10	0	Oct. 2009
Adrian Tsang – Genozymes	20.3	6	0	6	0	Oct. 2009
Peter Facchini/Vincent Martin – Phytometacyn	31	21	1	6	0	Oct. 2009
Richard Gold – VALGEN	20	10.6	1	2	0	Oct. 2009
TOTAL	**85.3**	**45.6**	**2**	**24**	**0**	
GQ HEALTH COMPETITION						
Gregor Andelfinger – Congenital Heart Disease			Sartup			Oct. 2010
Guy A. Rouleau – Bipolar Disorder			Sartup			Oct. 2010
Guy Sauvageau – Acute Myeloid Leukemia			Sartup			Oct. 2010
John H. White – Tuberculosis			Sartup			Oct. 2010
Ken Dewar – Digestive problems			Sartup			Oct. 2010
Mark Basik – Breast Cancer			Sartup			Oct. 2010
Michael Hallet – Breast Cancer			Sartup			Oct. 2010
Alain Moreau – Pediatric Scoliosis			Sartup			Oct. 2010
Michel G. Bergeron – Rapid Diagnostic Tests			Sartup			Oct. 2010
Maryam Tabrizian – Biosensors			Sartup			Oct. 2010
Paul Goodyer – Genetic Diseases			Sartup			Oct. 2010
Pavel Hamet – Type 2 Diabetes			Sartup			Oct. 2010
Gordon Shore/Michel L. Tremblay – Cancer Therapy			Sartup			Oct. 2010
TOTAL	**0**	**0**	**0**	**0**	**0**	
GQ PILOT PROJECTS COMPETITION						
Jamie Engert – Heart Disease			Sartup			Oct. 2010
Julie St-Pierre – Breast Cancer			Sartup			Oct. 2010
Pierre Drapeau/Edor Kabashi – New Therapeutic Approaches			Sartup			Oct. 2010
Roger C. Levesque – Ecogenomics			Sartup			Oct. 2010
Sarah Kimmins – Heredity			Sartup			Oct. 2010
Zoha Kibar – Neural Tube Defects			Sartup			Oct. 2010
TOTAL	**0**	**0**	**0**	**0**	**0**	
COMPETITION TOTAL (projects in progress)	**334.6**	**137.6**	**211**	**319**	**10**	

Competitions I & II, HEALTH

	Number of persons employed in year-person	Number of scientists trained in year-person	Number of publications accepted or submitted	Number of conferences as speaker	Number of declaration of inventions or patents	Project duration
Michel G. Bergeron – Theranostic Technologies	118	25	25	58	11	3.25 years
Deming Xu – Chemogenomics	32	2	8	4	1	3 years
Thomas Hudson – ARCTIC	42	6	19	15	9	3.25 years
Franz Lang – PEP Québec	49	21	20	18	0	3.5 years
Bussey/Michnick – Model Organisms	20	4	18	55	0	4 years
John Bergeron – Proteomics	174	67	42	125	7	4 years
Fernand Labrie – Atlas	347	120	49	29	2	5 years
Bartha Maria Knoppers – GEDS	38	20	83	153	0	4 years
Fathey Sarhan – Abiotic Stress Québec	82	28	11	17	0	4 years
Thomas Hudson – Regulatory Genetics	117	27	16	51	6	4 years
Rafick-Pierre Sékaly – S2K	194	79	17	150	6	4 years
Mario Filion – IGWH	36	5	1	10	4	3 years
Sherif Abou Elela – MoNa	51	8	6	9	2	3 years
Adrian Tsang – Fungal enzymes	167	69	16	22	8	3 years
Benoît Coulombe – Regulatory Networks	189	63	15	111	0	3.5 years
John MacKay – Arborea I	98	31	23	63	2	3.5 years
Thomas Hudson – Haplotype	34	2	14	87	1	3 years
Emil Skamene – Congenic Mice	60	13	2	11	3	4.25 years
Guy Rouleau – Ionic Channels	40	5	0	16	3	4.25 years
Terry Roemer – Candida albicans	51	0	2	3	3	3 years
Barry Posner/Rob Sladek – T2DM	5	0	25	35	6	Oct. 2004
Bartha Maria Knoppers – GPH	5	4	22	47	0	Jan. 2006
TOTAL COMPLETED PROJECTS	**1,949**	**599**	**434**	**1,089**	**74**	

MESSAGE FROM THE VICE PRESIDENT PUBLIC AFFAIRS AND COMMUNICATIONS

Marie-Kym Brisson
Vice President
Public Affairs and
Communications

In the last 10 years, genomics has grown by leaps and bounds. In 2000, for example, the price of mapping a human genome was in the billions, yet today we are talking in terms of one thousand dollars.

In Québec, scientists, decision makers and key players in life sciences went into overdrive to build on this vital sector. Genomics is now considered a strategic technology that holds great promise for Québec's economy. It is a leading-edge strategy that will play a vital role in several areas, including personalized medicine.

Over the last year, the governments of Québec and Canada have continued their strong support for genomics, setting the pace for the private sector to follow suit with its own investments.

Genomics is now considered a strategic technology that holds great promise for Québec's economy. It is a leading-edge strategy that will play a vital role in several areas, including personalized medicine.

In 2010-2011, to raise awareness among our key audiences, we organized the following public affairs activities:

- Meeting with federal and provincial Members of Parliament to present the socioeconomic benefits of genomics for today and tomorrow.
- Visit of Canada's Minister of Industry, the Honourable Tony Clement, to the McGill University and Génome Québec Innovation Centre. This productive meeting took place in the wake of presentations that opened the door to a $65 million investment by the Government of Canada (budget tabled on June 6th 2011).
- Presentation of our strategic plan to decision makers in Québec's innovation system.
- Participation in Genomics on the Hill, an event hosted by Genome Canada for Members of Parliament, Senators and other federal government representatives.
- Two announcements with Clément Gignac, Minister of Economic Development, Innovation and Export Trade: the first to unveil the projects selected through the Génome Québec competitions; the second to introduce Professor Mark Lathrop, a prominent researcher recruited by McGill University to serve as the Innovation Centre's Scientific Director.

In 2011-2012, we will continue to forge ahead with our awareness-raising efforts. We will carry out the strategic actions needed to rally key players around proactive initiatives, so that we may reach our ambitious objectives. Our goal is nothing less than the recognition of genomics' contribution to the collective wealth of Québec.

Marie-Kym Brisson
Vice President, Public Affairs and Communications

health
mobilization
collective wealth
prevention
future

OUTREACH AND EDUCATION ACTIVITIES

It was with great pride that Génome Québec, in partnership with the Québec Consortium for Drug Discovery (CQDM), launched in January 2011 a competition promoting the life sciences sector amongst Québec universities.

The goal of the *Défi Tweete tes neurones!* is to get young people interested in the issues faced by the life sciences sector, particularly on the communication front, and raise awareness of career challenges in this field.

Twenty-one teams – from McGill University, Laval, Université de Montréal, UQAM, UQTR and HEC Montréal – have signed up for the competition, with each of them being asked to develop a campaign promoting medical and biopharmaceutical research in Québec. Proposals were to be submitted by May 25th and finalists were selected by a jury on June 13th. The winning team, to be announced in September, will be awarded a $10,000 grant.

In keeping with our ongoing commitment to fuelling the interest of youth for careers in science, we launched phase 2 of *Génomia* last June. Through an "Escape the Room" concept, the interactive game explores four different science careers (lab technician, bioinformatics specialist, robotics engineer and genomics researcher). Since the introduction of the game in June 2009, the soil of *Génomia* has been virtually tread upon 106,815 times.

Phase 2 of *Génomia* was launched at the Eureka! Festival held in Montréal from June 11 to 13, 2010. The 600 or so visitors who came to the Génome Québec booth were given the chance to discover the role of the lab technician. What's more, through the *Génomia* Internet café, approximately 300 people took part in various interactive quests on the island. Developed with the financial support of the MDEIE, *Génomia* is available online free of charge.

In addition to attending the Eureka! Festival, Génome Québec also participated in several other outreach activities, such as the major scientific competition, Science Fair, aimed at promoting scientific literacy and careers in the field. For the past nine years now, Génome Québec has awarded the winner of the Québec Final a one-day internship at the McGill University and Génome Québec Innovation Centre.

The *Geee! in Genome* is yet another public exhibition intended to shed light on the field of genomics. Presented by Génome Québec at the Musée régional de Rimouski until May 2nd, this interactive event is an original educational initiative that makes the cutting-edge science of genomics accessible to all.

Finally, for a second year, Génome Québec has participated in the International Economic Forum of the Americas. Génome Québec and Montréal InVivo, in cooperation with the Cepmed, held a conference on personalized medicine, where world-leading experts discussed perspectives for patient organizations, healthcare professionals and public-private partnerships. They also presented highlights of work currently underway in the United States and Europe and underlined the benefits that are within reach for Canada.

Daniel Tessier
Senior Director Operations and Business Development

GÉNOME QUÉBEC TECHNOLOGY CENTRES

McGill University and Génome Québec Innovation Centre • For a seventh consecutive year, the Innovation Centre has boosted its client pool, this time by 12%. In fact, in 2010-2011, no less than 783 Canadian and international research teams called upon its services, compared to 704 the previous year. Of that number, an impressive 93% mentioned being satisfied or very satisfied with the services they received, as reported in a survey administered every year. A research team based in Cambridge, UK, has mandated the Centre to carry out genotyping on approximately 100,000 samples for a major study on cancer. This is by far the most ambitious project of its kind to be conducted at the Centre.

Also worthy of note is the appointment, this past February, of Professor Mark Lathrop as Scientific Director. The arrival of this prominent researcher confirms the Centre's repute and will bolster its recognition on the international scene. It was also concurrent with a tremendous expansion of the Centre's inventory of high-throughput sequencing equipment, now numbering 16 instruments.

Thanks to its reputation of excellence, the ongoing growth of its client base and the arrival of Professor Lathrop, the Innovation Centre did remarkably well at the *2010 Competition for Science and Technology Innovation Centre Operations Support* organized by Genome Canada. It not only ranked second in the Competition, it also secured $7.6 million in funding for its 2011-2013 operations and for the technological needs of 17 out of 30 national Genome Canada projects.

Génome Québec and Centre hospitalier affilié universitaire régional de Chicoutimi Biobank • In 2010-2011, the Biobank team focused mainly on CARTaGENE, helping to manage the biological samples collected among its cohort of participants. The blood and urine samples it received were processed for long-term storage in various forms. The urine, blood and plasma aliquots, and resulting DNA extracts are now stored under optimal conditions in the Biobank's secure vaults. They will be used for research in human health.

Génome Québec, Université de Montréal and CHUM NIML Centre • At the NIML Centre, the highlight of 2010-2011 was its move to Technopôle Angus, which went off smoothly without disrupting any of its activities. As such, the Centre continued with the clinical projects of its clients and pursued the development of innovative tools for evaluating immune responses.

Génome Québec and Université de Sherbrooke RNomics Centre • Génome Québec has reached an agreement with the Université de Sherbrooke on transferring the operation of the RNomics Centre to the University's Faculty of Medicine.

cutting edge
expertise
innovation
growth
support for science

Daniel Tessier
Senior Director, Operations
and Business Development

A decade after its founding, Génome Québec now has the net assets it needs for solid financial health. As a result, our organization enjoys greater flexibility and is extremely well positioned to launch new initiatives in genomics and meet extraordinary expenses should they arise.

efficiency
partnerships
financial health
explore
flexibility

This financial health is the direct result of positive actions carried out in recent years along two major lines. First, we have maximized the efficiency of our operations with thorough financial and accounting controls, good governance and sound management, particularly in terms of our Technology Centres. Second, emboldened by the support of the Ministry of Economic Development, Innovation and Export Trade, we have strengthened and extended our partnerships with key public and private actors in genomics, in Québec and Canada. In 2010-2011, we pursued our activities in keeping with these successful principles.

Denis Bilodeau
Vice President Administration

Our continued quest for greater efficiency has led us to create a new vice presidency of administration, which will oversee legal affairs, human resources and information technology, in addition to finance and investments. Again for reasons of efficiency, we have eliminated positions in some of our departments and restructured our Technology Centres. For example, the administrative staff of the Innovation Centre was relocated to our head office, allowing us to make better use of human resources and free up space for research personnel at the Innovation Centre.

Génome Québec has also explored new avenues for financing with several funders at the federal level. New alliances that complement our special partnership with Genome Canada should soon become a reality and open the door to competitions for Québec researchers. These relationships will not only benefit the scientific community here at home but will also help us to increase our leverage.

We can say with confidence that Génome Québec is starting 2011-2012 on the right foot. We have the right financial conditions that will allow us to consolidate our position as a key player in the field of genomics. In the coming fiscal year, two priorities will be taking our attention: we will continue to forge close ties with private and public financial partners, both provincial and federal, while pursuing efforts to consolidate, within a single entity, our operations in finance, investments, human resources, legal affairs and information technology.

We have the right financial conditions that will allow us to consolidate our position as a key player in the field of genomics.

Denis Bilodeau
Vice President, Administration

FINANCIAL ACTIVITY REPORT

As at March 31, 2011, our portfolio included 19 genomics and proteomics projects, for a total budget of $45.8 million. Génome Québec invested $39.7 million during the 2010-2011 fiscal year. This amount, combined with the $8.3 million invested by other partners in major research projects, brings our overall injection of funds to $48.0 million.

Genome Canada and Québec's Ministère du Développement économique, de l'Innovation et de l'Exportation (MDEIE) are Génome Québec's main funding agencies.

Business volume generated by the large-scale projects during the fiscal year represents $30.6 million. Major projects issued from the Competition III, PRIVAC, the Technological Development Competition and the P3G/CARTaGENE were completed during the year. The ABC Competition projects reached their cruising speed and the Génome Québec Human Health Competition projects were launched during this same period.

For the year ended at March 31, 2011, the Technology Centres sales totalled $12.2 million, a drop of 10% from the previous year. This decrease is primarily due to the transfer of the Pharmacogenomics Centre at the beginning of the fiscal year. Sales for the Innovation Centre showed an increase of 25% over last year. The Technology Centres posted an excess of revenue over expenses of $1.3 million. Of this total, $0.9 million was added to restricted net assets and $0.4 million to unrestricted net assets.

Génome Québec and Partners 2010-2011



Génome Québec and Activities Total investment of $48.0M



General and administrative expenses including communications and external committees (adjusted for non-recurring expenditures) totalled $3.5 million for the fiscal year, or 7.3% of total investments, the same amount as the previous year which represented 4.8% of total investments. Scientific Affairs activities increased whereas professional fees were lowered. Investment revenue reached $480,013, for a return of 2.4%.

During the fiscal year, the excess of revenue over expenses totalled $0.8 million. Unrestricted net assets rose by $460,560, for a total of $2.2 million. Unrestricted net assets represent a possible source of funding for future activities in keeping with Génome Québec's strategic development plans.

Génome Québec met the obligations and milestones provided for in its contractual agreements with major financial partners.

Jean-Marc Proulx
President and CEO

Denis Bilodeau
Vice President, Administration

To the Directors of Génome Québec

We have audited the accompanying financial statements of Génome Québec, which comprise the statement of financial position as at March 31, 2011, the statements of operations, changes in net assets and cash flows for the year then ended, and notes, comprising a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with Canadian generally accepted accounting principles, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Canadian generally accepted auditing standards. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statement.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements present fairly, in all material respects, the financial position of Génome Québec as at March 31, 2011, and its results of operations and its cash flows for the year then ended in accordance with Canadian generally accepted accounting principles..

KPMG LLP*

Chartered Accountants
June 7, 2011
Montréal, Canada

* CA Auditor permit no 14553

STATEMENT OF FINANCIAL POSITION

March 31, 2011, with comparative figures for 2010

	2011	2010
Assets		
Current assets:		
Cash and cash equivalents	$ 1,236,547	$ 1,411,970
Short-term investments	2,392,893	13,755,300
Accounts receivable and work in progress	2,609,172	1,607,579
Contribution receivable	14,000	–
Advances to genomic research projects	–	187,301
Inventories	605,707	663,605
Prepaid expenses	290,349	662,345
	7,148,668	**18,288,100**
Long-term investments (note 3)	29,305,338	10,341,635
Capital assets (note 4)	1,612,674	1,517,848
	$ 38,066,680	**$ 30,147,583**
Liabilities and Net Assets		
Current liabilities:		
Accounts payable and accrued liabilities	$ 3,337,538	$ 3,850,892
Deferred revenues	180,606	170,777
Due to genomic research projects	1,884,740	–
Contributions to be reimbursed (note 5 (i) and (ii))	2,448,194	1,348,170
	7,851,078	**5,369,839**
Deferred contributions:		
Future expenses (note 5)	25,607,372	20,346,136
Capital assets (note 6)	1,129,177	1,222,894
	26,736,549	**21,569,030**
Net assets:		
Unrestricted	2,181,214	1,720,654
Restricted – Invested in capital assets (note 4)	483,497	294,954
Restricted – Technology investment and contingency fund	814,342	1,193,106
	3,479,053	**3,208,714**
Commitments (note 9)		
	$ 38,066,680	**$ 30,147,583**

See accompanying notes to financial statements.

On behalf of the Board:



Director



Director

STATEMENT OF OPERATIONS

Year ended March 31, 2011, with comparative figures for 2010

	2011	2010
Revenues:		
Amortization of deferred contributions related to expenses (note 5)	$ 29,079,116	$ 35,116,000
Amortization of deferred contributions related to capital assets (note 6)	752,079	3,628,574
Investment income (note 7)	480,013	688,704
Revenues from technology centers	12,199,280	13,605,360
Revenues from intellectual property and others (note 7)	107,382	204,657
	42,617,870	**53,243,295**
Expenses:		
Genomic research projects	22,301,749	27,767,914
Technology centers operational cost	14,178,589	15,807,333
Projects – Technology investment and contingency fund	358,725	553,841
General and administrative	3,215,270	2,723,301
Communications and public outreach	335,686	281,181
External committees	213,022	212,302
Strategic initiatives	208,460	1,160,424
Depreciation of capital assets	752,079	3,628,574
Depreciation of restricted capital assets	258,502	170,497
	41,822,082	**52,305,367**
Excess of revenues over expenses	**$ 795,788**	**$ 937,928**

See accompanying notes to financial statements.

STATEMENT OF CHANGES IN NET ASSETS

Year ended March 31, 2011, with comparative figures for 2010

				2011
	Restricted		Unrestricted	Total
	Invested in capital assets	Technology investment and contingency fund		
Net assets, beginning of year	$ 294,954	$ 1,193,106	$ 1,720,654	$ 3,208,714
Excess of (expenses over revenues) revenues over expenses	(258,502)	952,455	101,835	795,788
Invested in capital assets	447,045	(447,045)	–	–
Invested in projects – Technology investment and contingency fund	–	(884,174)	358,725	(525,449)
Net assets, end of year	**$ 483,497**	**$ 814,342**	**$ 2,181,214**	**$ 3,479,053**

				2010
	Restricted		Unrestricted	Total
	Invested in capital assets	Technology investment and contingency fund		
Net assets, beginning of year	$ 394,254	$ 1,151,861	$ 724,671	$ 2,270,786
Excess of (expenses over revenues) revenues over expenses	(170,497)	645,269	463,156	937,928
Invested in capital assets	71,197	(50,183)	(21,014)	–
Invested in projects – Technology investment and contingency fund	–	(553,841)	553,841	–
Net assets, end of year	**$ 294,954**	**$ 1,193,106**	**$ 1,720,654**	**$ 3,208,714**

See accompanying notes to financial statements.

STATEMENT OF CASH FLOWS

Year ended March 31, 2011, with comparative figures for 2010

	2011	2010
Cash flows from operating activities:		
Excess of revenues over expenses	$ 795,788	$ 937,928
Adjustments for:		
Depreciation of capital assets	1,010,581	3,799,071
Amortization of deferred contributions related to expenses (note 5)	(29,079,116)	(35,116,000)
Amortization of deferred contributions related to capital assets (note 6)	(752,079)	(3,628,574)
	(28,024,826)	**(34,007,575)**
Contributions received	**36,098,738**	**32,646,009**
Changes in assets and liabilities:		
Accounts receivable and work in progress	(1,001,593)	649,879
Contribution receivable	(14,000)	2,065,872
Advances to genomic research projects	2,072,041	500,044
Inventories	57,898	500,823
Prepaid expenses	371,996	134,587
Accounts payable and accrued liabilities	(513,354)	342,878
Deferred revenues	9,829	(24,964)
	982,817	**4,169,119**
	9,056,729	**2,807,553**
Cash flows from investing activities:		
Change in short-term investments	11,362,407	(7,443,327)
Change in long-term investments	(18,963,703)	4,605,597
Purchase of capital assets	(1,105,407)	(1,130,273)
Disposition of technology investment and contingency fund (note 2)	(525,449)	–
	(9,232,152)	**(3,968,003)**
Net decrease in cash and cash equivalents	**(175,423)**	**(1,160,450)**
Cash and cash equivalents, beginning of year	**1,411,970**	**2,572,420**
Cash and cash equivalents, end of year	**$ 1,236,547**	**$ 1,411,970**

Additional information (note 7)

See accompanying notes to financial statements.

NOTES TO FINANCIAL STATEMENTS

Year ended March 31, 2011

Génome Québec (the "Corporation") was incorporated on June 29, 2000 under Section II of the *Canada Corporations Act*. Génome Québec is a not-for-profit organization and has the following objectives:

(a) to develop and maintain in the province of Quebec a coordinated approach and an integrated strategy in the fields of genomic research (including health, agriculture, environment, forestry and fisheries) by bringing together the intervening parties from the industry, governments, universities, research centers and laboratories, as well as any other person or organization interested in advancing the goals of the Corporation;

(b) to create, operate and support an infrastructure network in genomics giving Quebec researchers access to a high technology expertise;

(c) to ensure that researchers have access to the necessary equipment and installations to undertake research and development projects in genomics, and to allow for the training of researchers and technologists;

(d) to raise the awareness of the population to the necessity of research in genomics, to the usefulness and consequences of the outcome from this research, to ensure an ethical environment for the researchers and to contribute to public awareness regarding the stakes involved in genomic research.

1. Significant accounting policies:

The Corporation has elected to use the exemption provided by the Canadian Institute of Chartered Accountants ("CICA"). permitting not-for-profit organizations not to apply the following sections of the CICA Handbook: 3862 and 3863, which would otherwise have applied to the financial statements of the Corporation for the year ended March 31, 2011. The Corporation applies the requirements of Section 3861 of the CICA Handbook concerning the presentation and disclosures on financial instruments.

(a) Cash and cash equivalents:

Cash and cash equivalents consist of cash as well as all highly liquid short-term investments which have a maturity of less than three months from the date of acquisition.

(b) Investments:

Short-term investments and long-term investments, redeemable at any time, are recorded at the market value.

(c) Work in progress:

Work in progress is recorded at the pro rata billing value of the work completed.

(d) Inventories:

Inventories are represented by supplies which will be utilized by the technology centers. The supplies are recorded at the lower of cost and net realizable value. The cost is determined using the first in, first out method.

1. **Significant accounting policies** (continued):

(e) Advances and charges related to genomic research projects:

The advances represent the excess of the contributions to the research projects, including work performed by the technology centers, over the claims received which are recognized in the statement of operations.

(f) Revenue recognition:

The Corporation follows the deferral method of accounting for contributions which include mainly funding from Genome Canada and the ministère du Développement économique, de l'Innovation et de l'Exportation du Québec. Unrestricted contributions are recognized as revenue when received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured.

Externally restricted contributions are recognized as revenue in the year in which the related expenses are incurred. Restricted contributions related to the purchase of capital assets are deferred and amortized to revenues using the same methods and rates of the related capital assets.

Revenues from technology centers are sequencing, genotyping, biochip, biological sample storage, proteomics services and high throughput immunomonitoring lab tests. Revenues are recognized on the basis of the services rendered.

(g) Capital assets:

Capital assets are stated at cost. Depreciation is provided for using the following method and periods:

Asset	Method	Period
Furniture and fixtures	Straight-line	4 years
Equipment	Straight-line	Term of project and 4 years
Computers and software	Straight-line	3 years

(h) Use of estimates:

The preparation of financial statements in conformity with generally accepted accounting principles requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. Significant areas requiring the use of management's estimates relate to the determination of the useful life and the estimated residual value of the capital assets along with the recoverability of long-term investments. Accordingly, actual results could differ from those estimates.

NOTES TO FINANCIAL STATEMENTS (continued)
Year ended March 31, 2011

2. Restricted net assets:

Under agreements, the excess of revenues over expenses generated by these technology centers includes restrictions for its reinvestment:

For the Pharmacogenomics Center, the first $1,330,300 of the excess for the first four years ended March 31, 2010 was to be reinvested in the Centre as technology investment and contingency fund. As at April 19, 2010, the operation of the Center was transferred to the Montreal Heart Institute and the balance of contingency funds in the amount of $525,449.

For the RNomics Center, the excess must reimburse Génome Québec's financial contribution towards the start-up costs. As at March 31, 2011, the start-up costs total $583,122.

For the Innovation Center, the technology investment and contingency fund finances new technologies and pays for other expenses incurred by the center. The contributions represent a percentage of the revenues generated from services rendered to Genomics research projects and Canadian academics. As at March 31, 2011, the net assets total $570,127.

For the NIML Center, the excess of the two first operating years must be reinvested in the center as technology investment and contingency fund. As at March 31, 2011, the net assets total $244,215.

3. Long-term investments:

	2011	2010
Bonds, provincials, municipals and crown corporations, with a yield at cost, considering that the bond is held to maturity, between 2% and 5.4%, and a maturity ranging from April 2012 to September 2013	**$ 29,305,338**	**$ 10,341,635**

4. Capital assets:

			2011	2010
	Cost	Accumulated depreciation	Net book value	Net book value
Furniture and fixtures	$ 266,655	$ 254,518	$ 12,137	$ 22,325
Equipment – technology centers	9,985,687	9,005,479	980,208	1,000,770
Equipment – restricted assets – technology centers	1,071,794	588,297	483,497	294,954
Equipment - research projects	1,121,591	1,121,591	–	–
Computer and software	710,410	573,578	136,832	199,799
	$ 13,156,137	**$ 11,543,463**	**$ 1,612,674**	**$ 1,517,848**

5. Deferred contributions related to future expenses:

The Corporation receives contributions from Genome Canada and the ministère du Développement économique, de l'Innovation et de l'Exportation du Québec. These contributions will be administered and distributed in accordance with the terms and conditions of the related agreements.

Deferred contributions related to expenses of future periods represent the unspent externally restricted funding for the purposes of providing contributions to eligible recipients and paying operating and capital expenditures in future periods.

5. **Deferred contributions related to future expenses** (continued):

The deferred contributions are:

	Balance March 31, 2009	2010 Transactions	Balance March 31, 2010	2011 Transactions	Balance March 31, 2011
Contributions:					
Genome Canada	$ 155,680,111	$ 20,731,817	$ 176,411,928	$ 11,475,969	$ 187,887,897
Government of Québec	143,210,488	10,941,017	154,151,505	24,427,764	178,579,269
Canada Economic Development	1,546,089	583,911	2,130,000	–	2,130,000
VRQ	3,760,560	–	3,760,560	–	3,760,560
Cancer Care Ontario	3,592,213	389,264	3,981,477	130,655	4,112,132
Genome Prairies	1,947,093	–	1,947,093	–	1,947,093
FQRNT	500,000	–	500,000	–	500,000
FRSQ	439,000	–	439,000	–	439,000
MSSS	100,000	–	100,000	–	100,000
Natural resources	100,000	–	100,000	–	100,000
Other	71,851	–	71,851	64,350	136,201
	310,947,405	32,646,009	343,593,414	36,098,738	379,692,152
Investment income	2,871,270	–	2,871,270	–	2,871,270
Reclassification of completed projects (i)	(3,104,626)	–	(3,104,626)	(689,842)	(3,794,468)
Recovery of taxes on goods and services (ii)	905,557	–	905,557	(905,557)	–
Amount amortized to revenues	(267,540,294)	(35,116,000)	(302,656,294)	(29,079,116)	(331,735,410)
Amount invested in capital assets	(20,204,109)	(1,059,076)	(21,263,185)	(162,987)	(21,426,172)
	$ 23,875,203	**$ (3,529,067)**	**$ 20,346,136**	**$ 5,261,236**	**$ 25,607,372**

(i) The financial support of many research projects and current and capital expenses related to Competitions I, II and the Applied Genomics and Proteomics Research in Human Health ended on March 31, 2009 and on March 31, 2011. Contributions received in excess of the related accumulated expenses are reclassified as contributions to be reimbursed.

(ii) The Corporation received an opinion from the tax authorities allowing the recovery of the full amount of the goods and services input tax credit. Previously, the reimbursement was limited to a reduced rate. During the year, an amount of $495,375 was used to purchase capital assets. The remaining $410,182 is due to the provincial government and is presented as contributions to be reimbursed.

NOTES TO FINANCIAL STATEMENTS (continued)

Year ended March 31, 2011

6. Deferred contributions related to capital assets:

Deferred contributions related to capital assets represent the unamortized amount of contributions received for the purchase of capital assets. The amortization of such contributions is recorded as revenue in the statement of operations. The changes in balances of the deferred contributions are as follows:

	2011	2010
Opening balance	$ 1,222,894	$ 3,792,392
Add allocation of funding for capital asset purchases	162,987	1,059,076
Add recovery of taxes used to purchase capital assets (note 5 (ii))	495,375	–
Less amount amortized to revenues	(752,079)	(3,628,574)
Ending balance	**$ 1,129,177**	**$ 1,222,894**

7. Supplemental information:

	2011	2010
Statement of operations:		
Investment income:		
Interests	$ 480,013	$ 447,634
Dissolution of Émerillon Thérapeutiques	–	241,070
	$ 480,013	**$ 688,704**
Revenues from intellectual property and others:		
Contribution – Financed expenses of Innovation Center	$ 107,382	$ 194,000
Intellectual property	–	10,657
	$ 107,382	**$ 204,657**
Statement of cash flows:		
Non monetary transactions from the variance of deferred contributions:		
Amount transferred to deferred contributions related to capital assets	$ (162,987)	$ (1,059,076)
Amount of recovery taxes used to purchase capital assets	(495,375)	–
Amount reclassified as contribution to be reimbursed	(1,100,024)	–
	$ (1,758,386)	**$ (1,059,076)**

8. Financial instruments:

Fair value, credit risk and interest rate:

The Corporation determined that the book value of its short-term financial assets and liabilities, including cash and cash equivalents, short-term investments, accounts receivable and accounts payable and accrued liabilities, approximates their fair value due to the short-term nature of these instruments.

8. **Financial instruments** (continued):

The credit risk arises from the possibility of financial loss caused by the inability of a party to fulfill its contractual obligation. The Corporation performs ongoing monitoring of its risk exposure and takes appropriate actions to reduce the probability that such risk leads to losses.

Financial instruments that could expose the Corporation to important credit risk mainly consist of its investments in bonds. The Corporation's investment policy has been established to secure and protect capital so that current and future cash flow requirements can be met.

Bond investments consist primarily of fixed income securities issued by governmental and municipal organizations granted high credit rating. The weighted average yield at cost, considering that the bond is held to maturity, is 2.37%.

9. **Commitments:**

In accordance with agreements entered into with Genome Canada with regard to a financial support commitment of $101,307,521 related to Competition III, to the International Consortium Initiatives ("ICI"), to New Technology Development ("Tecdev"), to Competition ABC and to the Large-Scale Genomics Research Projects, the Corporation has agreed, among other things, to obtain equivalent financing commitments from other parties. In this matter, financial commitments from the Government of Québec amounted to $65,670,284 and an amount of $63,216,878 is committed from other parties.

In accordance with agreements entered into with the Government of Québec regarding a financial support of $66,165,346 related to the Privac Competition, Research Competition, to strategic initiatives and to administrative center costs, the Corporation has agreed to obtain financing commitments from other parties in the amount of $33,847,279, in regards to the Privac Competition, to the Human Health general stream and translational stream and to the Pilot Projects.

The Corporation's research projects portfolio totals $181,560,262. As of March 31, 2011, the residual balance for these projects totals $70,616,086.

The Corporation entered into various agreements for services, rents and purchase of capital assets. These agreements expire at various dates until 2016. The payments under these agreements for the coming years are:

2012	$ 337,933
2013	226,293
2014	230,912
2015	123,567
2016	85,458

10. **Comparative figures:**

Certain comparative figures for 2010 have been reclassified in order to conform with the financial statement presentation adopted in 2011.

MEMBERS OF THE BOARD OF DIRECTORS, COMMITTEES AND EMPLOYEES

BOARD OF DIRECTORS

Chairman of the Board
Gérald A. Lacoste, Q.C.
Corporate Director

Vice-Chairman of the Board
Jean-Claude Cadieux, PhD
Management Consultant

Secretary-Treasurer of the Board
Jean Brunet, *Lawyer*
Stein Monast L.L.P.

BOARD MEMBERS

Daniel Bouthillier, PhD, MBA
Consultant

Hélène Desmarais
Chairman of the Board and
Chief Executive Officer
Centre d'entreprises et
d'innovation de Montréal (CEIM)

Jean-Paul Gagné
Publisher Emeritus, Journal Les Affaires

Yves Joanette, PhD, FCAHS
President and CEO
Fonds de la recherche en santé
du Québec (FRSQ)

Pierre Prémont, PhD, FCA
President and CEO
Fonds québécois de la recherche
sur la nature et les technologies (FQRNT)

Jean-Marc Proulx, Eng., MBA
President and CEO
Génome Québec

Louise Proulx, PhD
Vice President
Vertex Pharmaceutiques (Canada) Inc.

Jacques Remacle, PhD
Principal Scientific Officer, Genomics
and Systemic Biology Unit
European Commission, Brussels

Luc Tanguay, MSc, CFA
Senior Executive Vice President and CFO
Theratechnologies Inc.

Paule Têtu, Eng.f.
Vice President, Strategic Development
Del Degan, Massé et associés

OBSERVERS

Pierre Meulien, PhD
President and CEO
Genome Canada

Geneviève Tanguay, PhD
Assistant Deputy Minister
Ministère du Développement économique,
de l'Innovation et de l'Exportation (MDEIE)

EXECUTIVE COMMITTEE

Chairman of the Committee
Gérald A. Lacoste, Q.C.
Corporate Director

Secretary of the Committee
Jean Brunet, *Lawyer*
Stein Monast L.L.P.

Jean-Claude Cadieux, PhD
Management Consultant

Jean-Paul Gagné
Journal Les Affaires

Jean-Marc Proulx, Eng., MBA
Génome Québec

Luc Tanguay, MSc, CFA
Theratechnologies Inc.

MANAGEMENT COMMITTEE

Jean-Marc Proulx
President and CEO

Marie-Kym Brisson
Vice President, Public Affairs
and Communications

Catalina Lopez Correa
Vice President, Scientific Affairs

Denis Bilodeau
Vice President, Administration

Daniel Tessier
Senior Director, Operations and
Business Development

GOVERNANCE COMMITTEE

Chairman of the Committee
Jean-Paul Gagné
Journal Les Affaires

Secretary of the Committee
Jean Brunet, *Lawyer*
Stein Monast L.L.P.

Daniel Bouthillier, PhD, MBA
Consultant

Gérald A. Lacoste, Q.C.
Corporate Director

Pierre Prémont, PhD, FCA
Fonds québécois de la recherche sur la nature et les technologies (FQRNT)

AUDIT/INVESTMENT COMMITTEE

Chairman of the Committee
Luc Tanguay, M.Sc., CFA
Theratechnologies Inc.

Jean-Claude Cadieux, PhD
Management Consultant

Louise Proulx, PhD
Vertex Pharmaceuticals (Canada) Inc.

STRATEGIC AND SCIENTIFIC ADVISORY BOARD (SSAB)

Chairman of the SSAB
Camille Limoges, PhD

Jo Bury, PhD, MBA
VIB

Mark McCarthy, PhD
Wellcome Trust, Oxford

Teri Manolio, MD, PhD
National Institutes of Health (NIH)

GÉNOME QUÉBEC EMPLOYEES

Anne-Marie Alarco
Yolaine Ancellin
Steve Arsenault
Vicky Arsenault
Lucian Avram
Kalil Ba
François-Marie Bacot
Guillaume Barreau
Yolande Bastien
Alexandre Bélisle
Line Benguerel
Denis Bilodeau
Michal Blazejczyk
Daniel Boismenu
Julie Boudreau
Martin Boulanger
Guillaume Bourque
Geneviève Bourret
Marie-Kym Brisson
Sébastien Brunet
David Bujold
François Cantin
Alice Carey
Emmanuelle Cartier
Raymond Castonguay
Valérie Catudal
Christine Cellier
Fanny Chagnon
Marie-Paule Choquette
Cristina Ciurli
Martin Constantineau
Catherine Côté
Nathalie Daigle
Geneviève Dancausse
Marcos Rafael Di Falco
Joana Dias
Haig Djambazian
Christian Drouin
Anick Dubois
Dale Einarson
Nathalie Émond
Joëlle Fontaine
Nancy Fournier
Pierre Francoeur
Rosalie Fréchette
Geneviève Geneau
Claire Goguen
Isabelle Guillet
Nathalie Hamel
Nathalie Hébert
Caroline Hébert-Benoit
Cecilia Hernandez
Abdelmadjid Hihi
Louis Dumond Joseph
Susan Khor
François Korbuly
Audrey Anne Kustec
André Laberge
Sylvie Laboissière
Marc-André Labonté
Philippe Laflamme
Claude Lamarre
Claire Landry
Alexandre Laverdure
Natacha Lebrasseur
Fabienne Lefebvre
Pierre Lepage
Darie Lessard
Louis Létourneau
Ginette Levasseur
Gary Leveque
Catalina Lopez Correa
Stéphanie Lord-Fontaine
Yannick Marcon
Aurélie Masurel
Marc Michaud
Jana Mickova
Nancy Milot
Alexandre Montpetit
Thuong Ngo
Daniel Pépin
Julie Perrone
André Ponton
Jean-Marc Proulx
Sylvie Renaud
Yannick Richard
Lyne Robert
Frédérick Robidoux
Sharen Sophie Roland
Jonathan Roux
Line Roy
Nicole Saati
Lorraine Saule
Laura Sbarra
Donna Sinnett
Andrea Smith
Dennis Spathis
Alfredo Staffa
Daniel Tessier
Marie-Catherine Tessier
Louise Thibault
Belisle Tir
Vincent Trudel
Julie Vallée
Tu Linh Van
Daniel Vincent
Hoai-Thu Vo
Patrick Willett
Hao Fan Yam
Chung-Yan Yuen
Corine Zotti

Séquençage complet du génome humain

Full Sequencing of the Human Genome

GenomeQuébec

2000

Création de Génome Québec

Génome Québec is founded

2001

Approbation du plan d'affaires Génome Québec par Jean Rochon, ministre de la Recherche, de la Science et de la Technologie

Lancement de cinq projets à grande échelle (concours I – Génome Canada) et création d'une plateforme de science et technologie – le Centre d'innovation Génome Québec et Université McGill

Jean Rochon, Minister of Research, Science and Technology, approves the Génome Québec business plan

Five large-scale projects are launched and a science and technology platform – the McGill University and Génome Québec Innovation Centre – is created (Competition I – Genome Canada)

2002

Début du projet Arborea – une référence mondiale dans le développement de la génomique des arbres – John MacKay et Jean Bousquet

Des chercheurs québécois jouent un rôle clé dans le Consortium international HapMap, visant à développer un outil essentiel à la découverte de gènes responsables des maladies

Lancement de dix projets à grande échelle (concours II – Génome Canada)

The Arborea Project, a global benchmark in the development of tree genomics, begins – John MacKay and Jean Bousquet

Québec researchers play a key role in the International HapMap Consortium aimed at developing the tools needed for the discovery of disease-causing genes

Ten large-scale projects are launched (Competition II – Genome Canada)

2003



Création du consortium international P^{3}G – un projet public de génomique des populations initié et présidé par Tom Hudson et Bartha Maria Knoppers

Inauguration du Centre d'innovation Génome Québec et Université McGill – Tom Hudson, directeur scientifique

International P^{3}G Consortium, a public population project in genomics, is created and chaired by Tom Hudson and Bartha Maria Knoppers

McGill University and Génome Québec Innovation Centre is inaugurated – Tom Hudson, Scientific Director

2004

Lancement de quatre projets à grande échelle (concours de recherche en génomique et en protéomique appliquée à la santé humaine – Génome Canada)

Four large-scale research projects are launched (Applied Genomics and Proteomics Research in Human Health Competition – Genome Canada)

2005

HapMap publie le premier catalogue complet des variations génétiques humaines, une réalisation historique qui accélère la recherche de gènes responsables de maladies courantes

Des chercheurs québécois percent le code génétique d'une souche virulente du *C. difficile* – Ken Dewar

Près de 68 000 personnes visitent l'exposition interactive Gén!e du génome au Centre des sciences de Montréal

Lancement de sept projets à grande échelle (concours III – Génome Canada)

HapMap publishes the first complete catalogue of human genetic variations, a historic milestone that accelerates research into genes involved in common diseases

Québec researchers decipher the genetic code of a virulent strain of C. difficile *– Ken Dewar*

Some 68,000 people visit the interactive exhibition The Geee! in Genome at the Montréal Science Centre

Seven large-scale projects are launched (Competition III – Genome Canada)

2006



Annonce d'un financement du MDEIE qui permet le lancement du concours PRIVAC, un concours québécois qui vise à financer des initiatives de recherche mixtes académique/privé en génomique

Identification d'une nouvelle cible thérapeutique pour le traitement du VIH par l'équipe de Rafick-Pierre Sékaly

Lancement d'un projet visant à identifier les déterminants de virulence du *C. difficile* – Ken Dewar

MDEIE announces funding, which leads to the launch of PRIVAC, a Québec competition aimed at financing academia/industry research initiatives

The Rafick-Pierre Sékaly research team identifies a new therapeutic target for the treatment of HIV

A project to identify the virulence determinants of C. difficile *is launched – Ken Dewar*

2007

Le Centre d'innovation, première organisation au Canada à offrir du séquençage à ultra haut débit

Science Watch classe au 5e rang mondial une percée dans la recherche sur le diabète réalisée par l'équipe de Rob Sladek

Génome Québec et Héma-Québec annoncent la création d'un registre de 22 000 donneurs génotypés pour faciliter le dépistage de sang compatible

HapMap publie la seconde génération de la « Carte d'haplotypes » du génome humain qui contient trois fois plus de marqueurs génétiques que la première version dévoilée en 2005

Lancement de CARTaGENE, une banque de données et de matériel biologique spécifique au Québec et création d'une biobanque d'envergure internationale au Saguenay

Lancement de quatre projets à grande échelle (concours PRIVAC – Génome Québec)

The Innovation Centre becomes the first organization in Canada to offer high-throughput sequencing

Science Watch ranks 5th in the world a research breakthrough in diabetes conducted by Rob Sladek and his team

Génome Québec and Héma-Québec announce the creation of a database of 22,000 genotyped donors to facilitate the screening of compatible blood

HapMap publishes the second-generation "haplotype map" of the human genome, which contains three times the genetic markers of the first version unveiled in 2005

CARTaGENE, a databank of biological material specific to Québec, is launched and a major international biobank is created in Saguenay

Four large-scale projects are launched (PRIVAC Competition – Génome Québec)

2008

Le Centre d'innovation – premier centre d'excellence *Sequenom* au monde

Création du Centre d'excellence en médecine personnalisée, en collaboration avec l'Institut de Cardiologie de Montréal

Percée dans le domaine du VIH : l'équipe de Rafick-Pierre Sékaly identifie une protéine qui combat l'immunodéficience

Des chercheurs canadiens (Rob Sladek et Constantin Polychronakos), français et britanniques effectuent une percée scientifique qui jette la lumière sur l'hyperglycémie grave

Lancement de deux projets (concours Développement de nouvelles technologies – Génome Canada)

The Innovation Centre becomes the first Sequenom *centre of excellence in the world*

A Centre of Excellence for personalized medicine is founded jointly with the Montreal Heart Institute

A breakthrough in HIV is made by Rafick-Pierre Sékaly and his team when it identifies a protein that fights immunodeficiency

Canadian (Rob Sladek and Constantin Polychronakos), French and British researchers make a breakthrough that sheds light on severe hyperglycemia

Two projects are launched (New Technology Development Competition – Genome Canada)

2009

Annonce d'un financement du MDEIE qui permet le lancement de quatre initiatives pour le soutien de la recherche en génomique au Québec

Lancement du recrutement des participants pour le projet CARTaGENE

Lancement de trois projets à grande échelle (concours Génomique appliquée aux bioproduits ou aux cultures – Génome Canada – Thomas Bureau, Adrian Tsang, Vincent Martin)

MDEIE announces funding, which leads to the launch of four programs in support of genomics research in Québec

Recruitment of CARTaGENE participants begins

Three large-scale projects are launched (Competition in Applied Genomics Research in Bioproducts or Crops – Genome Canada – Thomas Bureau, Adrian Tsang, Vincent Martin)

2010

Le Centre d'innovation – première organisation au Canada à obtenir la certification Illumina CSPro™ pour quatre applications

L'équipe de Guy A. Rouleau découvre un gène associé à une forme courante de migraine qui touche plus de six millions de Canadiens

Fin et succès de la phase de recrutement de CARTaGENE – l'objectif de 20 000 Québécois est atteint

Lancement de 19 projets de recherche en génomique (concours Génome Québec)

The Innovation Centre becomes the first organization in Canada to obtain Illumina CSPro™ certification for four applications

Guy A. Rouleau and his team discover a gene associated with a common type of migraine, which affects over six million Canadians

The CARTaGENE recruitment phase ends on a successful note – the objective of 20,000 Québec participants is reached

19 genomics research projects are launched (Génome Québec Competitions)

2011

Nomination de Mark Lathrop en tant que directeur scientifique du Centre d'innovation

Annonce de deux projets (concours de recherche appliquée à grande échelle de Génome Québec)

Mark Lathrop is appointed as Scientific Director of the Innovation Centre

Two projects are announced (Large-Scale Applied Research Competition – Génome Québec)